Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caris Life Sciences (CAI) EBITDA (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of EBITDA data on record, last reported at $82.1 million in Q4 2025.

  • For Q4 2025, EBITDA rose 321.74% year-over-year to $82.1 million; the TTM value through Dec 2025 reached $6.4 million, changed N/A, while the annual FY2025 figure was -$67.4 million, 76.1% up from the prior year.
  • EBITDA reached $82.1 million in Q4 2025 per CAI's latest filing, up from $32.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $82.1 million in Q4 2025 and bottomed at -$71.4 million in Q2 2025.